Gene Expression Profiling for MIS-C Myocarditis Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective prediction and management strategies for multisystem inflammatory syndrome (MIS-C) with severe myocarditis, particularly in children, and the risk of myocarditis post-SARS-CoV-2 vaccination, as well as the severity of COVID-19, due to limited understanding of underlying pathophysiological mechanisms and lack of reliable biomarkers.
Innovation Solution
A multi-parametric approach involving single-cell transcriptomic analyses and gene expression profiling to identify specific gene signatures in blood cells that correlate with the occurrence of myocarditis and disease severity, allowing for the prediction of MIS-C, severe COVID-19, and myocarditis post-vaccination by determining the expression levels of a defined set of genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional clinical monitoring methods are used, then basic disease tracking is possible, but prediction of MIS-C with severe myocarditis and disease severity cannot be reliably made
Solution Approach 1:
The patent introduces gene expression profiles as intermediary biomarkers that mediate between SARS-CoV-2 infection and the development of MIS-C with severe myocarditis. By measuring the expression levels of specific genes in blood cells, the method provides a reliable predictive tool that bridges the gap between initial infection and severe complications, enabling early identification of at-risk patients before clinical symptoms fully manifest.
2Measurement precision
If multi-parametric approach with single-cell transcriptomic analyses is applied, then prediction accuracy for MIS-C and severe myocarditis is improved, but method complexity increases
Solution Approach 1:
The patent segments the complex immune response into specific measurable gene expression components. By focusing on the expression levels of particular genes in specific cell types through single-cell transcriptomic analyses, the method breaks down the complex pathophysiology into quantifiable parameters that can be systematically measured and predicted, thereby improving accuracy while managing complexity through targeted measurement.
Solution Approach 2:
The patent utilizes changes in gene expression parameters as indicators of disease progression. By monitoring dynamic changes in the expression levels of specific genes rather than relying on static clinical parameters, the method achieves higher prediction accuracy for MIS-C and severe myocarditis, capturing the evolving nature of the immune response in a quantifiable manner.
3Loss of time
If early prediction of disease severity is achieved, then therapeutic decision-making is improved, but understanding of pathophysiological mechanisms remains limited
Solution Approach 1:
The patent enables preliminary identification of patients at risk for severe MIS-C with myocarditis by measuring gene expression profiles before clinical symptoms fully develop. This early prediction allows for preemptive therapeutic intervention, reducing the time to treatment and improving outcomes, while the gene expression data provides insights into the underlying pathophysiological mechanisms driving the disease progression.
Data Source
AI summary
SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases result in hyperinflammatory conditions often including myocarditis. To better understand these cases, the inventors applied a multi-parametric approach to the study of blood cells of 56 children hospitalized with suspicion of SARS-CoV-2 infection. The most severe forms of MIS-C (multisystem inflammatory syndrome in children related to SARS-CoV-2), that resulted in myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several chemokines. This phenotype was associated with TNF-α signaling, sustained NF-κB signaling in monocytic/dendritic cells, alongside increased HIF-1α and VEGF signaling. Single-cell transcriptomic analyses identified